J Psychopharmacol

Metabolic outcomes with cariprazine: New evidence from a meta-analysis

January 27, 2026

A systematic review and meta-analysis examined cariprazine's effects on metabolic parameters in patients with bipolar disorder and major depressive disorder. Nineteen studies were included, with 4 randomized trials contributing to the meta-analysis. Cariprazine demonstrated a favorable metabolic profile, with statistically significant but generally not clinically meaningful weight gain at 1.5‑mg and 3‑mg doses. No statistically significant changes were observed in fasting glucose, triglycerides, or cholesterol vs. placebo.

Clinical takeaway: Cariprazine may represent a metabolically safer antipsychotic option for patients with affective disorders, particularly those at elevated cardiometabolic risk.

Source:

Pompili M, et al. (2026, January 20). J Psychopharmacol. Effect of cariprazine on metabolic parameters in patients with affective disorders: A systematic review and meta-analysis. https://pubmed.ncbi.nlm.nih.gov/41558681/